Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240665 | 0.97 | — | — | |
| SCHEMBL962970 | 0.92 | — | — | |
| SCHEMBL6159120 | 0.87 | — | — | |
| SCHEMBL2301260 | 0.81 | CYP1A2 (0.33) | SHBGADH1ACYP1A2 | |
| SCHEMBL2301258 | 0.81 | CYP1A2 (0.33) | SHBGADH1ACYP1A2 | |
| SCHEMBL6033218 | 0.78 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL6956347 | 0.78 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL2303897 | 0.78 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL2303911 | 0.75 | — | — | |
| SCHEMBL6964611 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | claimed |
| US-20070249710-A1 | Biaromatic compounds and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-25 | — | — | US | claimed |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| US-20240166593-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| EP-4370106-A1 | CANNABIDIOLIC ACID ESTERS FOR TREATING PRADER-WILLI SYNDROME | EPM (IP), Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11970493-B2 | Autotaxin inhibitor compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-30 | — | — | US | disclosed |
| CN-117813081-A | Cannabidiol esters for the treatment of Prader-Willi syndrome | EPM(IP)公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024003906-A1 | CANNABINOID DERIVATIVES AND COMPOSITIONS COMPRISING SAME | CANNASOUL ANALYTICS LTD. (IL) | 2024-01-04 | — | — | WO | disclosed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4288104-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | Ramot at Tel-Aviv University Ltd. (IL) | 2023-12-13 | — | — | EP | disclosed |
| WO-1998054158-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998051324-A1 | PEPTIDE PARATHYROID HORMONE ANALOGS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998032734-A1 | SUBSTITUTED β-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | NPC1L1, NPC1, CETP | SHBG 4849/4885ADH1C 3192/4885ADH1A 4103/4885 |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | PDE4A, PDE4B, PDE6C | SHBG 4220/4885ADH1C 3511/4885ADH1A 3520/4885 |
| US-20240166593-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | NPC1L1, NPC1, FASN | SHBG 4850/4885ADH1C 2535/4885ADH1A 3192/4885 |
| US-11970493-B2 | Autotaxin inhibitor compounds | ENPP2, ATXN10, ATXN2L | SHBG 1767/4885ADH1C 4661/4885ADH1A 4761/4885 |
| US-20070249710-A1 | Biaromatic compounds and cosmetic/pharmaceutical applications thereof | RARG, RARA, RARB | SHBG 518/4885ADH1C 893/4885ADH1A 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.